STADA Arzneimittel (ETR:SAZ) received a €89.00 ($105.95) price target from research analysts at Independent Research in a report issued on Wednesday, December 20th. The brokerage presently has a “neutral” rating on the stock. Independent Research’s target price points to a potential upside of 0.38% from the company’s current price.
Several other equities research analysts have also recently weighed in on SAZ. Commerzbank set a €66.25 ($78.87) price objective on STADA Arzneimittel and gave the company a “sell” rating in a research report on Tuesday, August 22nd. S&P Global set a €74.40 ($88.57) price objective on STADA Arzneimittel and gave the company a “sell” rating in a research report on Friday, November 10th. Warburg Research set a €74.40 ($88.57) target price on STADA Arzneimittel and gave the company a “sell” rating in a research note on Wednesday, December 20th. Finally, Nord/LB set a €65.53 ($78.01) target price on STADA Arzneimittel and gave the company a “sell” rating in a research note on Thursday, August 31st. Four investment analysts have rated the stock with a sell rating and two have assigned a hold rating to the stock. The stock currently has an average rating of “Sell” and a consensus target price of €74.08 ($88.18).
Shares of STADA Arzneimittel (ETR SAZ) remained flat at $€88.66 ($105.55) during trading on Wednesday. The company had a trading volume of 29,454 shares, compared to its average volume of 56,226. The stock has a market cap of $5,530.00 and a P/E ratio of 58.33. STADA Arzneimittel has a 52 week low of €46.31 ($55.13) and a 52 week high of €89.76 ($106.86).
STADA Arzneimittel Company Profile
STADA Arzneimittel Aktiengesellschaft engages in the development and marketing of active pharmaceutical ingredients for the health care and pharmaceutical markets worldwide. It operates through two segments, Generics and Branded Products. The Generics segment provides various generic active ingredients, including Tilidine naloxone for pain; Atorvastatin for elevated cholesterol levels; Pantoprazole for stomach ulcer/reflux; Diclofenac for pain/inflammation; and Enalapril for high blood pressure indications.
Receive News & Ratings for STADA Arzneimittel Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for STADA Arzneimittel and related companies with MarketBeat.com's FREE daily email newsletter.